Breast Cancer Clinical Trial
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Poly ICLC may stop the growth of liver cancer by blocking blood flow to the tumor. Giving the drug directly into the arteries around the tumor may kill more tumor cells. Giving cyclophosphamide and radiation therapy together with poly ICLC may be an effective treatment for liver cancer.
PURPOSE: This phase I/II trial is studying the side effects of giving cyclophosphamide, radiation therapy, and poly ICLC together and to see how well they work in treating patients with unresectable, recurrent, primary, or metastatic liver cancer.
Full Description
OBJECTIVES:
To study the safety and effectiveness of a strategy to establish robust anticancer immunologic body defenses by using low-dose radiation therapy to the liver cancer in order to increase tumor targetability; inject a body defense activator, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC, hiltonol, oncovir), into and around the cancer to activate sentinel dendritic cells to alarm body defenses; and shut down local production of factors that suppress the body's natural anticancer defenses by starving the cancer of its blood supply within the liver.
OUTLINE: Patients receive low-dose oral cyclophosphamide once daily on days 1-21 and undergo 3-dimensional conformal radiotherapy on days 21-23. On day 24, patients undergo an intra- or peri-tumoral polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly ICLC) injection directly into the tumor followed by trans-hepatic artery embolization to the designated tumor. Patients receive poly ICLC subcutaneously on days 26, 35, 37, 42, 44, 49, and 51. Treatment repeats every 57 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months thereafter.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Radiologically or histologically confirmed hepatocellular carcinoma
Stage III or IV primary disease
Recurrent, unresectable, or metastatic disease meeting any of the following criteria:
Pancreatic cancer that underwent prior surgical resection and progressed with recurrent metastatic disease to the liver
Gastric, colon, breast, or ovarian cancer or melanoma with metastatic disease to the liver
Primary or recurrent disease that cannot be surgically resected leaving the patient disease-free
Radiologically measurable disease
Ineligible for liver transplantation according to University of San Francisco listing criteria:
Single lesion > 6.5 cm
Three or more tumors > 4.5 cm
Cumulative tumor diameter > 8 cm
PATIENT CHARACTERISTICS:
Karnofsky performance status 60-100%
ANC ≥ 1,500/mm³
Platelets ≥ 75,000/mm³
Creatinine ≤ 1.7 mg/dL
Total bilirubin ≤ 1.5 mg/dL
AST and ALT ≤ 3 times the upper limit of normal
INR < 1.5
LVEF ≥ 50%
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No serious concurrent infection or medical illness that would render the protocol treatment unsafe
LVEF ≥ 50%
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
No concurrent steroids
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Newark New Jersey, 07101, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.